1 Min Read
Sept 14 (Reuters) - Nymox Pharmaceutical Corp
* Says European member states for Nymox’s MAA for fexapotide triflutate for treatment of benign prostatic hyperplasia accepted co’s MAA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.